News

Afrezza, a rapid-acting inhaled insulin, is FDA-approved for use before meals for both type 1 and type 2 diabetes. The drug peaks in your blood in about 15-20 minutes and it clears your body in 2 ...
Sanofi cut the list price of Lantus by 78% to $96 for the prefilled pens and $64 for the 10-milliliter vial starting January 1. It reduced the list price of its short-acting Apidra insulin by 70%.
Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...
Currently, an estimated 37.3 million Americans (approximately 11.3% of the U.S. population) have diabetes, and roughly 8.4 million of them use insulin, according to the American Diabetes Association.
Lantus (insulin glargine) is a brand-name subcutaneous injection that’s prescribed for diabetes. It’s used in adults and some children. The cost of the drug with and without insurance can ...
Sanofi announced on March 16, 2023 that it will cut the US list price of Lantus (insulin glargine injection) 100 units/mL, a widely prescribed insulin, by 78%. The company will also establish a $35 ...
Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it ...
Sanofi's Lantus insulin injection will see its price cut by 78%, the company announced Thursday. The out-of-pocket cost for all patients will be $35 for a monthly supply.
Sanofi plans to take a 78% list-price reduction on Lantus, the company’s most widely used insulin in the U.S., and a 70% cut on its Apidra product starting in January 2024, the company said ...
One caveat: The pill called Bexacat can’t be used in cats like Oliver, who had previously received insulin. The biggest benefit may be the ease of use, experts said.